2-Decarboxy-2-hydroxymethyl-19-hydroxy-19-methyl-6-oxo-PGF.sub.1 compounds

- The Upjohn Company

The present invention provides novel 2-decarboxy-2-hydroxymethyl-19-hydroxy-19-methyl-6-oxo-PGF.sub.1 compounds which are useful for pharmacological purposes, e.g., anti-asthmatic indications.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
DESCRIPTION

1. BACKGROUND OF THE INVENTION

The present invention provides novel prostacyclin analogs. Particularly, the present invention relates to prostacyclin analogs substituted at the C-19 position by hydroxy.

Particularly, the present invention relates to 2-decarboxy-2-hydroxymethyl-19-hydroxy-19-methyl-6-oxo-PGF.sub.1 compounds. The novel prostacyclin analogs are useful for pharmacological purposes, e.g., as anti-asthmatic agents. The preparation and use of these compounds is incorporated here by reference from U.S. Ser. No. 054,720, filed July 5, 1979.

2. PRIOR ART

For background on prostacyclin, see for example R. A. Johnson, et al., Prostaglandins 12, 915-928 (1976) and R. A. Johnson, et al., J. Am. Chem. Soc. 100, 7690-7704 (1978), and, as to pharmacological activity, the references cited therein. For analogs of prostacyclin, see, for example, J. Fried, et al., Proc. Natl. Acad. Sci. U.S.A. 74, 2199-2203, K. C. Nicolaou, et al., J.C.S. Chem. Comm. 1977, 331-332, N. A. Nelson, J. Am. Chem. Soc. 99, 7362-7363 (1977), and K. Kojima, et al., Tetra. Letters, 1978, (1977), and K. Kojima, et al., Tetra. Letters, 1978, 3743-3746. Regarding the nomenclature for analogs of PGI.sub.2, see R. A. Johnson, et al., Prostaglandins 15, 737-740 (1978).

SUMMARY OF THE INVENTION

The present invention particularly provides

a prostacyclin-type compound of the formula ##STR1## wherein D is --(CH.sub.2).sub.2 --CO--CH.sub.2 --L.sub.2 -- or --CH.sub.2 --CO--CH.sub.2 --L.sub.3 --

wherein L.sub.2 is

(1) --(CH.sub.2).sub.j, wherein j is one to 4, inclusive,

(2) --(CH.sub.2).sub.q --CF.sub.2 --, wherein q is one, 2, or 3, or

(3) --CH.dbd.CH--,

wherein L.sub.3 is

(1) --(CH.sub.2).sub.n --, wherein n is one to 5, inclusive,

(2) --(CH.sub.2).sub.p --CF.sub.2 --, wherein p is 2, 3, or 4, or

(3) --CH.sub.2 --CH.dbd.CH--;

wherein Q is oxo, .alpha.-H:.beta.-H, .alpha.-OH:.beta.-R.sub.4, or .alpha.-R.sub.4 :.beta.-OH,

wherein R.sub.4 is hydrogen or alkyl of one to 4 carbon atoms, inclusive,

wherein R.sub.2 is hydrogen, hydroxyl, or hydroxymethyl;

wherein R.sub.5 and R.sub.6 are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R.sub.5 and R.sub.6 is fluoro only when the other is hydrogen or fluoro;

wherein X is

(1) trans--CH.dbd.CH--,

(2) cis--CH.dbd.CH--,

(3) --C.tbd.C--, or

(4) --CH.sub.2 CH.sub.2 --.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention particularly relates to the following compounds:

2-Decarboxy-2-hydroxymethyl-5-oxo-19-hydroxy-19-methyl-PGF.sub.1,

2-Decarboxy-2-hydroxymethyl-5-oxo-16,16-difluoro-19-hydroxy-19-methyl-PGF.s ub.1,

2-Decarboxy-2-hydroxymethyl-6-oxo-19-hydroxy-19-methyl-PGF.sub.1, and

2-Decarboxy-2-hydroxymethyl-6-oxo-16,16-difluoro-19-hydroxy-19-methyl-PGF.s ub.1.

Claims

1. A prostacyclin-type compound of the formula ##STR2## wherein D is --(CH.sub.2).sub.2 --CO--CH.sub.2 --L.sub.2 -- or --CH.sub.2 --CO--CH.sub.2 --L.sub.3 --

wherein L.sub.2 is
(1) --(CH.sub.2).sub.j, wherein j is one to 4, inclusive,
(2) --(CH.sub.2).sub.q --CF.sub.2 --, wherein q is one, 2, or 3, or
(3) --CH.dbd.CH--,
wherein L.sub.3 is
(1) --(CH.sub.2).sub.n --, wherein n is one to 5, inclusive,
(2) --(CH.sub.2).sub.p --CF.sub.2 --, wherein p is 2, 3, or 4, or
(3) --CH.sub.2 --CH.dbd.CH--;
wherein R.sub.4 is hydrogen or alkyl of one to 4 carbon atoms, inclusive,
(1) trans-CH.dbd.CH--,
(2) cis-CH.dbd.CH--,
(3) --C.tbd.C--, or
(4) --CH.sub.2 CH.sub.2 --.

2. A compound according to claim 1, wherein D is

--(CH.sub.2).sub.2 --CO--CH.sub.2 --L.sub.2 --, wherein L.sub.2 is --(CH.sub.2).sub.j, wherein j is one to 4, inclusive.

3. A compound according to claim 2, wherein D is

--(CH.sub.2).sub.2 --CO--CH.sub.2 --(CH.sub.2).sub.2 --, Q is.alpha.-OH:.beta.-H, R.sub.2 is hydroxyl, and X is trans-CH.dbd.CH--.

4. 2-Decarboxy-2-hydroxymethyl-5-oxo-19-hydroxy-19-methyl-PGF.sub.1, a compound according to claim 3.

5. 2-Decarboxy-2-hydroxymethyl- 5-oxo-16,16-difluoro-19-hydroxy-19-methyl-PGF.sub.1, a compound according to claim 3.

6. A compound according to claim 1, wherein D is

--CH.sub.2 --CO--CH.sub.2 --L.sub.3, wherein L.sub.3 is --(CH.sub.2).sub.n --, wherein n is one to 5, inclusive.

7. A compound according to claim 6, wherein D is

--CH.sub.2 --CO--CH.sub.2 --(CH.sub.2).sub.3 --, Q is.alpha.-OH:.beta.-H, R.sub.2 is hydroxyl, and X is trans-CH.dbd.CH--.

8. 2-Decarboxy-2-hydroxymethyl-6-oxo-19-hydroxy-19-methyl-PGF.sub.1, a compound according to claim 7.

9. 2-Decarboxy-2-hydroxymethyl- 6-oxo-16,16-difluoro-19-hydroxy-19-methyl-PGF.sub.1, a compound according to claim 7.

Referenced Cited
U.S. Patent Documents
4158667 June 19, 1979 Axen
Patent History
Patent number: 4252747
Type: Grant
Filed: Mar 3, 1980
Date of Patent: Feb 24, 1981
Assignee: The Upjohn Company (Kalamazoo, MI)
Inventor: John C. Sih (Kalamazoo, MI)
Primary Examiner: Robert Gerstl
Attorney: Robert A. Armitage
Application Number: 6/126,496
Classifications
Current U.S. Class: Five-membered Alicyclic Ring Containing (568/379); Halogen Containing (568/380)
International Classification: C07C17700;